0% found this document useful (0 votes)
5 views9 pages

Method Development

The document outlines the method development for HPLC analysis of the drug Etelcalcetide, detailing the necessary equipment, chemicals, and standard preparation. It includes solubility studies, various chromatographic trials, and the optimized conditions for analysis, such as the mobile phase composition and flow rate. The final optimized method demonstrates effective separation and quantification of Etelcalcetide with improved peak characteristics.
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
5 views9 pages

Method Development

The document outlines the method development for HPLC analysis of the drug Etelcalcetide, detailing the necessary equipment, chemicals, and standard preparation. It includes solubility studies, various chromatographic trials, and the optimized conditions for analysis, such as the mobile phase composition and flow rate. The final optimized method demonstrates effective separation and quantification of Etelcalcetide with improved peak characteristics.
Copyright
© All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as DOCX, PDF, TXT or read online on Scribd

METHOD DEVELOPMENT

6. METHOD DEVELOPMENT
Materials and Instruments:

The following are the list of instruments/Equipments, chemicals/reagents and standards to


perform the HPLC Analysis of the drug Etelcalcetide.

Equipments:

Table-5.1: List of Equipments


[Link]. Instruments/Equipments/Apparatus

1. HPLC WATERS with Empower2 Software with Isocratic with UV-Visible


Detector.

2. T60-LABINDIA UV – Vis spectrophotometer


3. High Precision Electronic Balance
4. Ultra Sonicator (Wensar wuc-2L)

5. Thermal Oven

6. Symmetry C18 Column, 250 mm x 4.6 mm and 5µm particle size

7. PH Analyser (ELICO)

8. Vaccum Filtration Kit (Labindia)

Chemicals and Reagents:

Table-5.2: List of Chemicals used

[Link]. Name Grade Manufacturer/Supplier

1. HPLC grade water HPLC Sd fine-Chem ltd; Mumbai

2. Methanol HPLC Loba Chem; Mumbai.

3. Ethanol A.R. Sd fine-Chem ltd; Mumbai

Department of Pharmaceutical Analysis Page 1


METHOD DEVELOPMENT

4. Acetonitrile HPLC Loba Chem; Mumbai.

5. DMSO A.R. Sd fine-Chem ltd; Mumbai

6. DMF A.R. Sd fine-Chem ltd; Mumbai

Working Standard: Working Standard of Etelcalcetide: 10ppm

Solubility Study:

Table-5.3: Solubility Results

Solvents Solubility

Methanol Soluble

Ethanol Soluble

Acetonitrile Soluble

DMSO Soluble

Dichloromethane Soluble

Chloroform Soluble

Water Practically Insoluble in


Water
Hydrochloric acid Sparingly Soluble

HPLC Instrumentation & Conditions: The HPLC system employed was HPLC WATERS
with Empower2 Software with Isocratic with UV-Visible Detector.

Standard Preparation for UV-Spectrophotometer Analysis:

The Standard Stock Solutions – 10 mg of Etelcalcetide standard was transferred into 10 ml


volumetric flask, dissolved & make up to volume with Methanol. Further dilutions were done

Department of Pharmaceutical Analysis Page 2


METHOD DEVELOPMENT

by transferring 1 ml of the above solution into a 10ml volumetric flask and make up to volume
with methanol to get 10ppm concentration.

It scanned in the UV spectrum in the range of 200 to 400nm. This has been performed to know
the maxima of Etelcalcetide, so that the same wave number can be utilized in HPLC UV detector
for estimating the Etelcalcetide.

Fig-: Double Beam UV Spectrophotometer

Fig-: UV-Spectrum for Etelcalcetide

Observation: While scanning the Etelcalcetide solution we observed the maxima at 245nm.

DIFFERENT TRIALS FOR CHROMATOGRAPHIC CONDITIONS

Department of Pharmaceutical Analysis Page 3


METHOD DEVELOPMENT

Table-: Different Chromatographic Conditions

Column Used Mobile Phase Flow Wave Observatio Result


Rate length n

Zorbax C18, 250 mm Methanol : 0.9 245nm Extra peaks Method


x 4.6 mm and 5µm Acetonitrile = 30 : 70 ml/min rejected
Column

Phenomenex C18, 250 Methanol : 1.0 245nm Stabilizatio Method


mm x 4.6 mm and Acetonitrile = 60 : 40 ml/min n was not rejected
5µm Column Good

Symmetry C18, 250 Methanol : 1.0 245nm Improper Method


mm x 4.6 mm and Acetonitrile ml/min peak rejected
5µm Column
= 50 : 50 separation

Symmetry C18, 250 Methanol : Phosphate 1.0 245nm Tailing Method


mm x 4.6 mm and Buffer (0.01M) (pH- ml/min peaks rejected
5µm Column 2.8)

= 40 : 60

Symmetry C18, 250 Methanol : Phosphate 1.0 245nm Tailing Method


mm x 4.6 mm and Buffer (0.02M) (pH- ml/min peaks rejected
5µm Column 3.2)

= 60 : 40

Symmetry C18, 250 Methanol : Phosphate 1.0 245nm Proper Method


mm x 4.6 mm and Buffer ml/min Peak Accepted
5µm Column
(0.02M) (pH-3.8)

= 70 : 30

Department of Pharmaceutical Analysis Page 4


METHOD DEVELOPMENT

Fig-: Chromatogram for Trial-1


Table-: Results of Chromatogram for Trial-1

[Link]. Peak Name Rt Peak Area Height USP Tailing USP Plate Count

1 Etelcalcetide 2.970 45867 2546 2.18 2168

Fig-: Chromatogram for Trial-2


Table-: Results of Chromatogram for Trial-2

[Link]. Peak Name Rt Peak Area Height USP Tailing USP Plate Count

1 Etelcalcetide 3.539 45867 2546 2.18 2168

Department of Pharmaceutical Analysis Page 5


METHOD DEVELOPMENT

Fig- 5.7: Chromatogram for Trial-3


Table-5.8: Results of Chromatogram Trial-3

[Link]. Peak Name Rt Peak Area Height USP Tailing USP Plate Count

1 Etelcalcetide 4.660 685975 42548 1.57 3659

Fig- 5.7: Chromatogram for Trial-4


Table-5.8: Results of Chromatogram Trial-4

[Link]. Peak Name Rt Peak Area Height USP Tailing USP Plate Count

1 Etelcalcetide 2.497 685975 42548 1.57 3659

Department of Pharmaceutical Analysis Page 6


METHOD DEVELOPMENT

Fig- 5.7: Chromatogram for Trial-5


Table-5.8: Results of Chromatogram Trial-5

[Link]. Peak Name Rt Peak Area Height USP Tailing USP Plate Count

1 Etelcalcetide 2.720 685975 42548 1.57 3659

Fig-: Chromatogram for Trial-6


Table-: Results of Chromatogram Trial-6

[Link]. Peak Name Rt Peak Area Height USP Tailing USP Plate Count

1 Etelcalcetide 2.775 715268 47844 1.35 5857

Department of Pharmaceutical Analysis Page 7


METHOD DEVELOPMENT

Optimized Chromatographic Conditions:

Column : Symmetry C18, 250 mm x 4.6 mm i.d.5µm particle size


Mobile Phase : Methanol: Phosphate Buffer (0.02M) (pH-3.8) (70: 30% v/v)
Flow Rate : 1.0ml/minute
Wave length : 245 nm
Injection volume : 10 µl
Run time : 7 minutes
Column temperature : Ambient

Fig-: Chromatogram for Blank Solution

Fig-: Optimized Chromatogram for Etelcalcetide

Department of Pharmaceutical Analysis Page 8


METHOD DEVELOPMENT

Table-: Results of Optimized Chromatogram

[Link]. Peak Name Rt Peak Area Height USP Tailing USP Plate Count

1 Etelcalcetide 2.775 715268 47844 1.35 5857

Preparation of 0.02M Phosphate Buffer (pH-3.8): Prepare 800 mL of distilled water in a


suitable container. Add 2.72172g of Potassium dihydrogen Phosphate to the solution to the
solution. Adjust solution to final desired pH 3.8 using diluted solution of orthophosphoric acid
and add distilled water until volume is 1 Litre.

Preparation of Mobile Phase: Mix a mixture of 0.02M Phosphate Buffer (pH-3.8) 700 ml
(70%) and 300 ml Methanol HPLC (30%) and degas in ultrasonic water bath for 15 minutes.
Filter through 4.5 µ filter under vacuum filtration.

Preparation of Standard Solution:

Accurately weigh and transfer 10 mg of Etelcalcetide working standard into a 10ml of clean dry
volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make
volume up to the mark with the same solvent. (Stock solution)

Further pipette out 0.1ml of Etelcalcetide from the above stock solutions into a 10ml volumetric
flask and dilute up to the mark with Diluent.

Result: The selected and optimized mobile phase was Methanol: Phosphate Buffer (70: 30%
v/v) and conditions optimized were flow rate (1.0 ml/minute), wavelength (245nm), Run time
was 07 mins. Here the peak has shown better theoretical plate count and symmetry. The
proposed chromatographic conditions were found appropriate for the quantitative determination
of the Etelcalcetide drug.

Department of Pharmaceutical Analysis Page 9

You might also like